3,001 Shares in IQVIA Holdings Inc. (NYSE:IQV) Purchased by Aristeia Capital L.L.C.

Aristeia Capital L.L.C. acquired a new stake in IQVIA Holdings Inc. (NYSE:IQV) in the second quarter, Holdings Channel.com reports. The firm acquired 3,001 shares of the medical research company’s stock, valued at approximately $635,000.

Other large investors have also made changes to their positions in the company. Canada Pension Plan Investment Board lifted its holdings in IQVIA by 6.6% during the second quarter. Canada Pension Plan Investment Board now owns 3,403,488 shares of the medical research company’s stock valued at $719,634,000 after purchasing an additional 211,653 shares in the last quarter. Lazard Asset Management LLC boosted its holdings in IQVIA by 0.9% in the 1st quarter. Lazard Asset Management LLC now owns 3,263,944 shares of the medical research company’s stock worth $825,416,000 after buying an additional 30,014 shares during the last quarter. Farallon Capital Management LLC increased its stake in IQVIA by 3.1% during the 2nd quarter. Farallon Capital Management LLC now owns 2,923,032 shares of the medical research company’s stock worth $618,046,000 after buying an additional 86,870 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in shares of IQVIA by 3.8% in the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,510,685 shares of the medical research company’s stock valued at $634,927,000 after acquiring an additional 92,293 shares in the last quarter. Finally, Capital Research Global Investors boosted its stake in shares of IQVIA by 7.2% in the first quarter. Capital Research Global Investors now owns 2,138,802 shares of the medical research company’s stock worth $540,882,000 after acquiring an additional 143,533 shares during the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts have weighed in on the company. JPMorgan Chase & Co. raised their price objective on IQVIA from $260.00 to $288.00 and gave the company an “overweight” rating in a report on Monday, August 5th. Argus upgraded shares of IQVIA to a “strong-buy” rating in a report on Wednesday, July 31st. StockNews.com upgraded IQVIA from a “hold” rating to a “buy” rating in a report on Thursday, September 5th. UBS Group increased their price target on IQVIA from $295.00 to $300.00 and gave the company a “buy” rating in a report on Tuesday, July 23rd. Finally, Barclays upped their target price on IQVIA from $255.00 to $275.00 and gave the company an “overweight” rating in a report on Tuesday, July 23rd. Four equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $267.00.

Insider Activity at IQVIA

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of the business’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total transaction of $320,229.00. Following the sale, the insider now directly owns 19,536 shares in the company, valued at $4,812,302.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.60% of the stock is currently owned by company insiders.

IQVIA Price Performance

IQVIA stock opened at $240.75 on Tuesday. The company has a debt-to-equity ratio of 1.80, a quick ratio of 0.85 and a current ratio of 0.85. The company has a market capitalization of $43.86 billion, a price-to-earnings ratio of 32.89, a price-to-earnings-growth ratio of 2.25 and a beta of 1.49. The company’s 50 day simple moving average is $240.90 and its 200-day simple moving average is $233.81. IQVIA Holdings Inc. has a 1 year low of $167.42 and a 1 year high of $261.73.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Monday, July 22nd. The medical research company reported $2.64 EPS for the quarter, topping analysts’ consensus estimates of $2.57 by $0.07. IQVIA had a return on equity of 28.59% and a net margin of 9.39%. The company had revenue of $3.81 billion for the quarter, compared to analysts’ expectations of $3.79 billion. During the same period in the prior year, the firm earned $2.22 earnings per share. The firm’s revenue was up 2.3% compared to the same quarter last year. As a group, equities research analysts expect that IQVIA Holdings Inc. will post 10.25 earnings per share for the current year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.